A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK (NIO-SILK)
A Randomized, Participant & Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of Intrathecally Administered NIO752 to Lower CSF Total Tau Synthesis in Participants With AD Measured by Stable Isotope Labelling Kinetics
Sponsor: Alzheimer's Association
Listed as NCT06372821, this PHASE1 trial focuses on Alzheimer Disease and Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder) and remains actively recruiting participants. Sponsored by Alzheimer's Association, it has been updated 5 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Aug 2025 — Feb 2026 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Aug 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alzheimer's Association
- Sigrid Rausing Trust
- University College, London
- University of Washington
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .